Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Publishing timestamp: 2024-09-08 08:00:01
Summary
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients in the earliest stages of the disease more time to live normally and independently. However, the road to treatment is long and complicated due to various hurdles such as reimbursement uncertainties, diagnostic test requirements, and difficulties finding neurologists. Despite the challenges, some patients and caregivers believe the risk and grueling process is worth it for the potential benefits of the drug. The rollout of Leqembi has been gradual, but efforts are being made to make the treatment more convenient for patients in the future.
Sentiment: MIXED
Tickers: BIIB, 4523.T-JP, ESALY,
Keywords: pharmaceuticals, breaking news, biogen inc, health care industry, biotech and pharmaceuticals, breaking news: business, alzheimer's disease, eisai co ltd, science, business, biotechnology, business news,
Source: https://www.cnbc.com/2024/09/08/leqembi-alzheimers-patients-biogen-eisai.html